Progenics Pharmaceuticals (PGNX) Stock Price, Quote, News and Overview
NASDAQ:PGNX - Nasdaq -
PGNX Quote, Performance and Key Statistics
4.1
-0.43 (-9.39%)
The current stock price of PGNX is 4.1 null. In the past month the price increased by 4.59%. In the past year, price decreased by -21.15%.
About PGNX
Company Profile
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
Company Info
Progenics Pharmaceuticals
ONE WORLD TRADE CENTER 47TH FLOOR
NEW YORK NY 10007
CEO: David W. Mims
Phone: 646-975-2500
Progenics Pharmaceuticals / PGNX FAQ
What is the stock price of Progenics Pharmaceuticals today?
The current stock price of PGNX is 4.1 null. The price decreased by -9.39% in the last trading session.
What is the ticker symbol for Progenics Pharmaceuticals stock?
The exchange symbol of Progenics Pharmaceuticals is PGNX and it is listed on the Nasdaq exchange.
On which exchange is PGNX stock listed?
PGNX stock is listed on the Nasdaq exchange.
What is Progenics Pharmaceuticals worth?
Progenics Pharmaceuticals (PGNX) has a market capitalization of 355.05M null. This makes PGNX a Small Cap stock.
What are the support and resistance levels for Progenics Pharmaceuticals (PGNX) stock?
Progenics Pharmaceuticals (PGNX) has a support level at 3.98 and a resistance level at 4.5. Check the full technical report for a detailed analysis of PGNX support and resistance levels.
Should I buy Progenics Pharmaceuticals (PGNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PGNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PGNX, evaluating the profitability, health, valuation and growth aspects
- Progenics Pharmaceuticals (PGNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Progenics Pharmaceuticals (PGNX) Sales and EPS estimates to see what analysts future expectations are.
- Progenics Pharmaceuticals (PGNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Progenics Pharmaceuticals (PGNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- Progenics Pharmaceuticals (PGNX) Stock Chart to make your own analysis
- Progenics Pharmaceuticals (PGNX) Latest news and press-releases to stay up to date.
Does Progenics Pharmaceuticals (PGNX) stock pay dividends?
PGNX does not pay a dividend.
What is the Price/Earnings (PE) ratio of Progenics Pharmaceuticals (PGNX)?
Progenics Pharmaceuticals (PGNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.77).
PGNX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to PGNX. When comparing the yearly performance of all stocks, PGNX is one of the better performing stocks in the market, outperforming 85.06% of all stocks.
PGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PGNX. Both the profitability and financial health of PGNX have multiple concerns.
PGNX Financial Highlights
Over the last trailing twelve months PGNX reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS decreased by -13.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -180.28% | ||
| ROA | -67.74% | ||
| ROE | N/A | ||
| Debt/Equity | 0.99 |
PGNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 100% to PGNX. The Buy consensus is the average rating of analysts ratings from 1 analysts.